fulllogo_transparent_nobuffer Aanastra.png
Aanastra Inc to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024
02 mai 2024 06h30 HE | Aanastra Inc
Aanastra showcases its peptide-RNA therapeutics targeting p53, KRAS and BRCA-1 driven cancers, hemophilia A and PCSK9 for hypercholestrolemia at ASGCT
fulllogo_transparent_nobuffer Aanastra.png
Aanastra Inc to Present Multiple Posters on RNA Therapeutics at the American Association for Cancer Research (AACR) Annual Meeting 2024
03 avr. 2024 06h30 HE | Aanastra Inc
Aanastra to present its RNA peptide therapeutics technology at AACR conference
Verve-Logo-RGB-Color-wTrademark.png
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
07 nov. 2023 06h30 HE | Verve Therapeutics
U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Collaboration with Eli Lilly and...
Verve-Logo-RGB-Color-wTrademark.png
Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
31 oct. 2023 06h01 HE | Verve Therapeutics
BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...
前沿生物与AFFiRiS宣布就靶向PCS
前沿生物与AFFiRiS宣布就靶向PCSK9的高胆固醇血症治疗药物AFFITOPE®AT04达成大中华区许可协议
22 déc. 2021 04h00 HE | AFFiRiS AG
前沿生物获得在大中华区开发与商业化AFFITOPE®AT04的独家权利合作旨在加快AFFITOPE®AT04主动免疫疗法作为同类首创新药的全球开发进程,推动其在大中华区的临床开发和生产落地 中国南京和奥地利维也纳, Dec. 22, 2021 (GLOBE NEWSWIRE) --...
AFFiRiS and Frontier
AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China
22 déc. 2021 04h00 HE | AFFiRiS AG
Frontier Biotechnologies obtains exclusive rights to develop and commercialize AFFITOPE® AT04 in Greater China Collaboration accelerates the global development of AFFiRiS potential first-in-class...
AFFiRiS: Positive ph
AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology
27 mai 2021 05h00 HE | AFFiRiS AG
Repeated immunization with AFFITOPE® peptide active immunotherapy candidates AT04A and AT06A is safe, well-tolerated and induces a strong and long-lasting PCSK9-specific immune responseAT04A treatment...
Shifa Biomedical Corporation Presents Preclinical Data on P-21, a Novel Orally Active PSCK9 Antagonist, at the American Heart Association (AHA) Meeting, Scientific Sessions 2018
12 nov. 2018 12h30 HE | Shifa Biomedical
CHICAGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Shifa Biomedical Corporation (Shifa), a drug discovery biopharmaceutical company focused on developing novel agents to treat cardiovascular disease and...
Esperion Logo (primary).png
Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor
26 juil. 2017 16h30 HE | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 26, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
NLA LOGO - USE.png
PCSK9 Barriers Survey Results Revealed at National Lipid Association Conference
07 févr. 2017 09h30 HE | National Lipid Association
PHOENIX, AZ--(Marketwired - February 07, 2017) - As part of its Spring Clinical Lipid Update (CLU) in Phoenix, the National Lipid Association (NLA) will reveal the results of its "Challenges in...